Probiotic Research in Therapeutics -

Probiotic Research in Therapeutics (eBook)

Volume 5: Metabolic Diseases and Gut Bacteria
eBook Download: PDF
2022 | 1st ed. 2022
XIV, 275 Seiten
Springer Nature Singapore (Verlag)
978-981-16-8444-9 (ISBN)
Systemvoraussetzungen
213,99 inkl. MwSt
  • Download sofort lieferbar
  • Zahlungsarten anzeigen
This volume focuses on the potential use of probiotics in treating metabolic disorders such as diabetes mellitus, metabolic acidosis, and gut dysbiosis. Chapters draw an association between gut microbiota and its diversity with metabolic diseases like diabetes, obesity, related liver and gut disorders; gut-brain axis; increased inflammation, and a compromised immune system resulting from these manifestations and scope of intervention with probiotics. Special attention is laid on describing the mechanisms of action of such beneficial effects of probiotic administration. The ability of probiotics to decrease metabolic endotoxemia by restoring the disrupted intestinal mucosal barrier is also included.

The volume is a comprehensive compilation describing the scope and application of probiotic and prebiotic therapy in treating metabolic disorders. Readers will discover how probiotics are not just confined to the microbiology industry but are showing promising results in the medical and pharmaceutical sectors.


Dr. Indu Pal Kaur is presently working as the Professor and Chairperson at the University Institute of Pharmaceutical Sciences (UIPS). She has more than 25 years of teaching and research experience. Her research forte enhances the performance of small and large biomolecules, including probiotics using active-tailored delivery systems. The emphasis of her work lies in Industrial and clinical translation. She has delivered 50 Invited Talks; published > 145 high impact International publications and 21 book chapters; edited four books and 4 Journal special issues; and > 150 presentations have been made by her research group, with 30 sentenced as best presentations. 

Prof. Kanwaljit Chopra, the former Chairperson of the University Institute of Pharmaceutical Sciences, has prolific experience of 28 years in research and holds distinguished expertise in Neuropharmacology, Diabetes & Metabolic Diseases, Pain, Inflammation, and Menopausal complications. She has more than 215 international and national publications in high-impact journals, acclaimed globally for her research work. She has received eleven prestigious national and international awards. She has fetched grants of over 1.5 Crores from the Government as well as Industry. She has been an active member of National and International societies. Her 'Reverse Pharmacology' approach has provided strong leads to the scientific community for the translational potential of various moieties of natural origin. 
Dr. Mahendra Bishnoi is working as Scientist E, Food and Nutritional Biotechnology, National Agri-Food Biotechnology Institute, Mohali. He is presently leading a group of young researchers dedicated to metabolic disorders (obesity and type-2 diabetes) research with a particular focus on nutrition and diet, the development of molecular evidence-based functional foods, and nutraceuticals. His scientific work is well recognized in more than 120 peer-reviewed and high-impact factor scientific journals, with around 4000 citations. Dr. Bishnoi is an Alexander von Humboldt Experienced Fellow, Early and Mid-Career Research (EMCR) fellow of Indian National Science Academy (INSA), Melvin Yahr awardee from World Federation of Neurosciences. 

Dr. Kondepudi is presently working as Scientist-E in the Food & Nutrition Biotechnology Division at National Agri-Food Biotechnology Institute, an autonomous institute under the Department of Biotechnology, Government of India. Dr. Kondepudi is actively working on developing dietary interventions that could beneficially modulate the gut bacteria and could protect from proinflammatory stress underlying many diseases with an overall goal to develop functional foods based on millets and their bioactive ingredients, dietary fibers, prebiotics, probiotics, and other functional ingredients from different plant sources. His group uses rodent models, nutrigenomic and metagenomic approaches for evaluating the efficacy of bioactive ingredients and functional foods.

This volume focuses on the potential use of probiotics in treating metabolic disorders such as diabetes mellitus, metabolic acidosis, and gut dysbiosis. Chapters draw an association between gut microbiota and its diversity with metabolic diseases like diabetes, obesity, related liver and gut disorders; gut-brain axis; increased inflammation, and a compromised immune system resulting from these manifestations and scope of intervention with probiotics. Special attention is laid on describing the mechanisms of action of such beneficial effects of probiotic administration. The ability of probiotics to decrease metabolic endotoxemia by restoring the disrupted intestinal mucosal barrier is also included.The volume is a comprehensive compilation describing the scope and application of probiotic and prebiotic therapy in treating metabolic disorders. Readers will discover how probiotics are not just confined to the microbiology industry but are showing promising results in the medical and pharmaceutical sectors.
Erscheint lt. Verlag 4.5.2022
Mitarbeit Chef-Herausgeber: Indu Pal Kaur
Zusatzinfo XIV, 275 p. 1 illus.
Sprache englisch
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Pharmakologie / Pharmakotherapie
Medizin / Pharmazie Pflege
Medizin / Pharmazie Pharmazie PTA / PKA
Studium Querschnittsbereiche Infektiologie / Immunologie
Naturwissenschaften Chemie Analytische Chemie
Technik
Schlagworte Designer probiotics • Gut dysbiosis • Metabolic acidosis • Metabolic Endotoxemia • Micrbiome • Regulatory requirements • safety concerns
ISBN-10 981-16-8444-8 / 9811684448
ISBN-13 978-981-16-8444-9 / 9789811684449
Informationen gemäß Produktsicherheitsverordnung (GPSR)
Haben Sie eine Frage zum Produkt?
PDFPDF (Wasserzeichen)
Größe: 5,0 MB

DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasser­zeichen und ist damit für Sie persona­lisiert. Bei einer missbräuch­lichen Weiter­gabe des eBooks an Dritte ist eine Rück­ver­folgung an die Quelle möglich.

Dateiformat: PDF (Portable Document Format)
Mit einem festen Seiten­layout eignet sich die PDF besonders für Fach­bücher mit Spalten, Tabellen und Abbild­ungen. Eine PDF kann auf fast allen Geräten ange­zeigt werden, ist aber für kleine Displays (Smart­phone, eReader) nur einge­schränkt geeignet.

Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

Mehr entdecken
aus dem Bereich
Antibiotika, Virostatika, Antimykotika, Antiparasitäre Wirkstoffe

von Hans-Reinhard Brodt; Achim Hörauf; Michael Kresken …

eBook Download (2023)
Thieme (Verlag)
164,99
Mit den neuen Preisen vom 1.8.2024

von Peter M. Hermanns; Enrico Schwartz; Katharina von Pannwitz

eBook Download (2024)
Springer Berlin Heidelberg (Verlag)
64,99